Solving complex issues in lipidology: 2+3!

Introduction. From September 26 to 28, 2024, the Russian National Congress of Cardiologists, one of the key annual events for cardiologists and specialists from related fields, took place in St. Petersburg. The goal of the Congress is to promote the modernization of the healthcare system, improve the quality of specialized care, and reduce morbidity and mortality from cardiovascular diseases. A satellite symposium, "Solving Complex Issues in Lipidology: 2+3!", chaired by Doctors of Medical Sciences G. P. Arutyunov and M. V. Ezhov, was dedicated to the challenges of modern treatments of dyslipidemia, one of the key risk factors for cardiovascular diseases.

Objective. The aim of this work is to review the presentations given at the symposium, to inform medical specialists about the latest developments in lipid-lowering therapy and the positions of international and new Russian clinical guidelines on the management of patients with lipid metabolism disorders. The review focuses on the issues and evidence regarding the efficacy, tolerability, and safety of statin therapy across various patient groups.

1. Zhang X., Patel A., Horibe H., et al. Cholesterol, coronary heart disease, and stroke in the Asia Pacific region. International Journal of Epidemiology. 2003; 32 (4): 563-572. DOI: 10.1093/ije/dyg106.

2. Mortality rates in Russia in 2018. Federal State Statistics Service. Accessed: October 13, 2024. Available: https://www.gks.ru/folder/12781. (In Russ.)

3. Mortality from cardiovascular diseases in the Russian Federation. Federal State Statistics Service. Accessed: October 13, 2024. Available: https://rosstat.gov.ru. (In Russ.)

4. Mortality from cardiovascular diseases in the Russian Federation. Federal State Statistics Service. Accessed: October 13, 2024. Available: https://rosstat.gov.ru. (In Russ.)

5. Ray K. K., Ezhov M. V., Santos R. D., et al. World Heart Federation Cholesterol Roadmap 2022. Global Heart. 2022; 17 (1): 75. DOI: 10.5334/gh.1154.

6. Braunwald E. The Cardiology in 2022. European Heart Journal. 2022; 43 (4): 249-250. DOI: 10.1093/eurheartj/ehab532.

7. Shalnova S. A., Deev A. D., Metelskaya V. A., et al. Awareness and treatment specifics of statin therapy in persons with various cardiovascular risk: the study ESSE-RF. Kardiovaskulyarnaya terapiya i profilaktika. 2016; 15 (4): 29-37. (In Russ.) DOI: 10.15829/1728-8800-2016-4-29-37

8. Gitt A. K., Drexel H., Feely J., et al. Persistent lipid abnormalities in statintreated patients and predictors of LDL-cholesterol goal attainment in clinical practice in Europe and Canada. European Journal of Preventive Cardiology. 2012; 19 (2): 221-230. DOI: 10.1177/1741826711400545.

9. Mach F., Baigent C., Catapano A. L., et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal. 2020; 41 (1): 111-188. DOI: 10.1093/eurheartj/ehz455.

10. Boekholdt S. M., Hovingh G. K., Mora S., et al. Very low levels of atherogenic lipoproteins and risk for cardiovascular events: a meta-analysis of statin trials. Journal of the American College of Cardiology. 2014; 64 (5): 485-494. DOI: 10.1016/j.jacc.2014.02.615.

11. Ezhov M. V., Lazareva N. V., Sagajdak O. V., et al. Prevalence of lipid disorders and statin use in acute coronary syndrome (data from the Federal Registry of Acute Coronary Syndrome). Journal of Ateroskleroz i Dislipidemii. 2018; 1 (30): 47-57. (In Russ.)

12. Clinical Guidelines 752. Lipid Metabolism Disorders. Approved by the Scientific and Practical Council of the Ministry of Health of the Russian Federation. Available: cr.minzdrav.gov.ru/recomend/752_1. (In Russ.)

13. Pirillo A., Tokgözoğlu L., Catapano A. L. European Lipid Guidelines and Cardiovascular Risk Estimation: Current Status and Future Challenges. Current Atherosclerosis Reports. 2024; 26 (5): 133-137. DOI: 10.1007/s11883-024-01194-7.

14. Kronenberg F., Mora S., Stroes E. S. G., et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. European Heart Journal. 2022; 43 (39): 3925-3946. DOI: 10.1093/eurheartj/ehac361.

15. Soffer D. E., Marston N. A., Maki K. C., et al. Role of apolipoprotein B in the clinical management of cardiovascular risk in adults: An expert clinical consensus from the national lipid association. Journal of clinical lipidology. 2024; S1933–2874(24)00240-X. DOI: 10.1016/j.jacl.2024.08.013.

16. Diagnosis and correction of lipid metabolism disorders for the prevention and treatment of atherosclerosis. Russian recommendations, VII revision, 2020. (In Russ.)

17. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Journal of Hepatology. 2016; 64 (6): 1388-1402. DOI: 10.1016/j.jhep.2015.11.004.

18. Chazova I. E., Ageev F. T., Aksenova A. V., et al. Eurasian clinical guidelines for cardiovascular complications of cancer treatments: diagnosis, prevention and treatment (2022). Evraziiskii Kardiologicheskii Zhurnal. 2022; (1): 6-79. (In Russ.) DOI: 10.38109/2225-1685-2022-1-6-79.

19. Lyon A. R., López-Fernández T., Couch L. S., et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). European Heart Journal. 2022; 43 (41): 4229-4361. DOI: 10.1093/eurheartj/ehac244.

20. Storhaug C. L., Fosse S. K., Fadnes L. T. Country, regional, and global estimates for lactose malabsorption in adults: a systematic review and metaanalysis. Lancet Gastroenterology & Hepatology. 2017; 2 (10): 738-746. DOI: 10.1016/S2468-1253(17)30154-1.

21. Instructions for the use of the medicinal product Rozulip® Plus. Registration certificate LP-№(000228)-(RG-RU). (In Russ.)

22. State Register of Medicines. Available: https://grls.rosminzdrav.ru. (In Russ.)

23. Ibanez B., Fernández-Ortiz A., Fernández-Friera L., et al. Progression of Early Subclinical Atherosclerosis (PESA) Study: JACC Focus Seminar 7/8. Journal of the American College of Cardiology. 2021; 78 (2): 156-179. DOI: 10.1016/j.jacc.2021.05.011.

24. Nissen S. E. Effect of intensive lipid lowering on progression of coronary atherosclerosis: evidence for an early benefit from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial. American Journal of Cardiology. 2005; 96 (5A): 61F-68F. DOI: 10.1016/j.amjcard.2005.07.013.

25. Nicholls S. J., Ballantyne C. M., Barter P. J., et al. Effect of two intensive statin regimens on progression of coronary disease. New England Journal of Medicine. 2011; 365 (22): 2078-2087. DOI: 10.1056/ NEJMoa1110874.

26. Puri R., Nissen S. E., Ballantyne C. M., et al. Factors underlying regression of coronary atheroma with potent statin therapy. European Heart Journal. 2013; 34 (24): 1818-1825. DOI: 10.1093/eurheartj/eht084.

27. Tsujita K., Sugiyama S., Sumida H., et al. Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients With Percutaneous Coronary Intervention. Journal of the American College of Cardiology. 2015; 66 (5): 495-507. DOI: 10.1016/j.jacc.2015.05.065.

28. Meng P. N., Yin D. L., Lu W. Q., et al. Intensive statin versus low-dose statin + ezetimibe treatment for fibrous cap thickness of coronary vulnerable plaques. Chinese Medical Journal (Engl). 2020; 133 (20): 241-2421. DOI: 10.1097/CM9.0000000000001067.

29. Masuda J., Tanigawa T., Yamada T., et al. Effect of combination therapy of ezetimibe and rosuvastatin on regression of coronary atherosclerosis in patients with coronary artery disease. International Heart Journal. 2015; 56 (3): 278-285. DOI: 10.1536/ihj.14-311.

30. Lee Y. J., Cho J. Y., You S. C., et al. Moderate-intensity statin with ezetimibe vs. high-intensity statin in patients with diabetes and atherosclerotic cardiovascular disease in the RACING trial. European Heart Journal. 2023; 44 (11): 972-983. DOI: 10.1093/eurheartj/ehac709.

31. Farnier M., Santos R. D., Cosin-Sales J., et al. Projected impact of treatment intensification with statin, ezetimibe, and statin plus ezetimibe fixed-dose combination on MACE across six countries. European Journal of Preventive Cardiology. 2022; 29 (17): 2264-2271. DOI: 10.1093/eurjpc/zwac214.

32. Ezhov M. V., Akhmedzhanov N. M., Kolmakova T. E., et al. Outpatient Practice of Lipid-Lowering Therapy Prescription (According to the ARGO-3 Study). Rational Pharmacotherapy in Cardiology. 2023; 19 (2): 143-150. DOI:10.20996/1819-6446-2023-04-04.

33. Adherence to long-term therapies: evidence for action. 2003. World Health Organization. Available: https://iris.who.int/handle/10665/42682.

34. Lazebnik L. B., Golovanova E. V., Turkina S. V., et al. Non-alcoholic fatty liver disease in adults: clinic, diagnostics, treatment. Guidelines for therapists, third version. Eksperimentalnaya i klinicheskaya gastroenterologiya. 2021; 1 (1): 4-52. (In Russ.) DOI: 10.31146/1682-8658-ecg-185-1-4-52.

35. Kanwal F., Neuschwander-Tetri B. A., Loomba R., Rinella M. E. Metabolic dysfunction–associated steatotic liver disease: Update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver disease. Hepatology. 2024; 79 (5): 1212-1219. DOI: 10.1097/HEP.0000000000000670.

36. Oni E. T., Agatston A. S., Blaha M. J., et al. A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care?. Atherosclerosis. 2013; 230 (2): 258-267. DOI: 10.1016/j.atherosclerosis.2013.07.052.

37. Targher G., Day C. P., Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. New England Journal of Medicine. 2010; 363 (14): 1341-1350. DOI: 10.1056/NEJMra0912063.

38. Calori G., Lattuada G., Ragogna F., et al. Fatty liver index and mortality: the Cremona study in the 15th year of follow-up. Hepatology. 2011; 54 (1): 145-152. DOI: 10.1002/hep.24356.

39. Dongiovanni P., Petta S., Mannisto V., et al. Statin use and nonalcoholic steatohepatitis in at-risk individuals. Journal of Hepatology. 2015; 63 (3): 705-712. DOI: 10.1016/j.jhep.2015.05.006.

40. Athyros V. G., Tziomalos K., Gossios T. D., et al. Safety and efficacy of longterm statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet. 2010; 376 (9756): 1916-1922. DOI: 10.1016/S0140-6736(10)61272-X.

41. Tikkanen M. J., Fayyad R., Faergeman O., et al. Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels. International Journal of Cardiology. 2013; 168 (4): 3846-3852. DOI: 10.1016/j.ijcard.2013.06.024.

42. Chalasani N., Aljadhey H., Kesterson J., et al. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology. 2004; 126 (5): 1287-1292. DOI: 10.1053/j.gastro.2004.02.015.

43. Chalasani N., Younossi Z., Lavine J. E., et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018; 67 (1): 328-357. DOI: 10.1002/hep.29367.

44. Newman C. B., Preiss D., Tobert J. A., et al. Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association. Arteriosclerosis, Thrombosis, and Vascular Biology. 2019; 39 (2): e38-e81. DOI: 10.1161/ATV.0000000000000073.

45. Giral P., Neumann A., Weill A., Coste J. Cardiovascular effect of discontinuing statins for primary prevention at the age of 75 years: a nationwide population-based cohort study in France. European Heart Journal. 2019; 40 (43): 3516-3525. DOI: 10.1093/eurheartj/ehz458.

46. Rosenson R. S., Baker S. K., Jacobson T. A., et al. The National Lipid Association's Muscle Safety Expert Panel. An assessment by the Statin Muscle Safety Task Force: 2014 update. Journal Of Clinical Lipidology. 2014; 8 (3 Suppl): S58-71. DOI: 10.1016/j.jacl.2014.03.004.

47. Stroes E. S., Thompson P. D., Corsini A., et al. European Atherosclerosis Society Consensus Panel, Statin-associated muscle symptoms: impact on statin therapy – European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. European Heart Journal. 2015; 36 (17): 1012-1022. DOI: 10.1093/eurheartj/ehv043.

48. Schleyer T., Hui S., Wang J., et al. Quantifying Unmet Need in StatinTreated Hyperlipidemia Patients and the Potential Benefit of Further LDL-C Reduction Through an EHR-Based Retrospective Cohort Study. Journal of Managed Care & Specialty Pharmacy. 2019; 25 (5): 544. DOI: 10.18553/jmcp.2019.25.5.544.

49. Ezhov M. V., Pogorelova O. A., Tamaeva B. M., et al. Effect of fixed doses of rosuvastatin and ezetimibe on arterial stiffness in the carotid basin (DRUZHBA). Ateroskleroz i Dislipidemii. 2024; 3 (56): 73-83. (In Russ.) DOI: 10.34687/2219-8202.JAD.2024.03.0007.